CY1114480T1 - Συνθεσεις που περιλαμβανουν διαχωρισμενο αγωνιστη υποδοχεα γλυκοκορτικοειδους για τη θεραπεια ή τον ελεγχο φλεγμονης προσθιου τμηματος - Google Patents

Συνθεσεις που περιλαμβανουν διαχωρισμενο αγωνιστη υποδοχεα γλυκοκορτικοειδους για τη θεραπεια ή τον ελεγχο φλεγμονης προσθιου τμηματος

Info

Publication number
CY1114480T1
CY1114480T1 CY20131100807T CY131100807T CY1114480T1 CY 1114480 T1 CY1114480 T1 CY 1114480T1 CY 20131100807 T CY20131100807 T CY 20131100807T CY 131100807 T CY131100807 T CY 131100807T CY 1114480 T1 CY1114480 T1 CY 1114480T1
Authority
CY
Cyprus
Prior art keywords
treatment
control
cortic
infection
compositions containing
Prior art date
Application number
CY20131100807T
Other languages
English (en)
Inventor
Keith Wayne Ward
Claudio Bucolo
Original Assignee
Bausch & Lomb Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb Incorporated filed Critical Bausch & Lomb Incorporated
Publication of CY1114480T1 publication Critical patent/CY1114480T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Σύνθεση για θεραπευτική αγωγή ή έλεγχο φλεγμονώδους ασθένειας ή πάθησης πρόσθιου τμήματος που περιλαμβάνει διαχωρισμένο αγωνιστή υποδοχέα γλυκοκορτικοειδούς (“DIGRA”: dissociated glucocorticoid receptor agonist). Η σύνθεση μπορεί προαιρετικά να περιλαμβάνει αντιφλεγμονώδη παράγοντα, αντιλοιμώδη παράγοντα, ή και τα δύο. Η σύνθεση μπορεί να τυποποιηθεί για τοπική χορήγηση, ένεση, ή εμφύτευση στο πρόσθιο τμήμα του οφθαλμού ή σε παρακείμενο ιστό αυτού.
CY20131100807T 2007-08-10 2013-09-18 Συνθεσεις που περιλαμβανουν διαχωρισμενο αγωνιστη υποδοχεα γλυκοκορτικοειδους για τη θεραπεια ή τον ελεγχο φλεγμονης προσθιου τμηματος CY1114480T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95504407P 2007-08-10 2007-08-10
EP08797177.6A EP2190431B1 (en) 2007-08-10 2008-08-05 Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation

Publications (1)

Publication Number Publication Date
CY1114480T1 true CY1114480T1 (el) 2016-10-05

Family

ID=40263555

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100807T CY1114480T1 (el) 2007-08-10 2013-09-18 Συνθεσεις που περιλαμβανουν διαχωρισμενο αγωνιστη υποδοχεα γλυκοκορτικοειδους για τη θεραπεια ή τον ελεγχο φλεγμονης προσθιου τμηματος

Country Status (19)

Country Link
US (1) US20090042936A1 (el)
EP (1) EP2190431B1 (el)
JP (1) JP5209718B2 (el)
KR (2) KR20120113802A (el)
CN (1) CN101969950A (el)
AU (1) AU2008287142B2 (el)
BR (1) BRPI0815130A2 (el)
CA (1) CA2694227C (el)
CY (1) CY1114480T1 (el)
DK (1) DK2190431T3 (el)
ES (1) ES2421405T3 (el)
HK (1) HK1141249A1 (el)
HR (1) HRP20130631T1 (el)
MX (1) MX2010001370A (el)
PL (1) PL2190431T3 (el)
PT (1) PT2190431E (el)
SI (1) SI2190431T1 (el)
TW (1) TWI410252B (el)
WO (1) WO2009023471A2 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US10278810B2 (en) * 2010-04-29 2019-05-07 Ojo, Llc Injectable physiologically adaptive intraocular lenses (IOL's)
US20120316199A1 (en) * 2011-06-07 2012-12-13 Ward Keith W Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
WO2020152193A1 (en) 2019-01-22 2020-07-30 Akribes Biomedical Gmbh Selective glucocorticoid receptor modifiers for treating impaired skin wound healing
US20200330270A1 (en) * 2019-04-18 2020-10-22 Teeny Clean, Llc Device And Method For Stimulating The Meibomian Glands Of The Eyelid

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6242196B1 (en) * 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
EP1117406A1 (en) * 1998-09-30 2001-07-25 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ES2276038T3 (es) * 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
US6903215B2 (en) * 2002-03-26 2005-06-07 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003230700A1 (en) * 2002-03-26 2003-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP4503436B2 (ja) * 2002-07-08 2010-07-14 ファイザー・プロダクツ・インク 糖質コルチコイド受容体のモジュレーター
CA2512257A1 (en) * 2003-01-03 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2006525011A (ja) * 2003-04-30 2006-11-09 ファイザー・プロダクツ・インク 白内障形成リスクに関するスクリーニング法
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
US20050234091A1 (en) * 2004-03-22 2005-10-20 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7417056B2 (en) * 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
US7635711B2 (en) * 2004-12-27 2009-12-22 Boehringer-Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2007032556A1 (ja) * 2005-09-14 2007-03-22 Santen Pharmaceutical Co., Ltd. グルココルチコイド受容体結合活性を有する新規１，２−ジヒドロキノリン誘導体
ATE531366T1 (de) * 2006-08-07 2011-11-15 Bausch & Lomb Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments
EP2364707B1 (en) * 2006-08-07 2013-04-03 Bausch & Lomb Incorporated Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof
EP2056799B1 (en) * 2006-08-31 2013-07-31 Bausch & Lomb Incorporated Compositions and methods for treating or preventing glaucoma or progression thereof
US8193187B2 (en) * 2007-05-29 2012-06-05 Santen Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye

Also Published As

Publication number Publication date
BRPI0815130A2 (pt) 2017-05-09
CN101969950A (zh) 2011-02-09
AU2008287142B2 (en) 2012-02-02
KR20120113802A (ko) 2012-10-15
KR101298826B1 (ko) 2013-08-27
PT2190431E (pt) 2013-10-09
US20090042936A1 (en) 2009-02-12
MX2010001370A (es) 2010-03-01
PL2190431T3 (pl) 2013-11-29
EP2190431A2 (en) 2010-06-02
SI2190431T1 (sl) 2013-10-30
JP5209718B2 (ja) 2013-06-12
WO2009023471A2 (en) 2009-02-19
WO2009023471A3 (en) 2009-06-25
KR20100029851A (ko) 2010-03-17
HK1141249A1 (en) 2010-11-05
CA2694227C (en) 2012-07-03
TWI410252B (zh) 2013-10-01
HRP20130631T1 (hr) 2013-08-31
ES2421405T3 (es) 2013-09-02
TW200911286A (en) 2009-03-16
EP2190431B1 (en) 2013-07-03
DK2190431T3 (da) 2013-09-08
AU2008287142A1 (en) 2009-02-19
JP2010535796A (ja) 2010-11-25
CA2694227A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CY1114480T1 (el) Συνθεσεις που περιλαμβανουν διαχωρισμενο αγωνιστη υποδοχεα γλυκοκορτικοειδους για τη θεραπεια ή τον ελεγχο φλεγμονης προσθιου τμηματος
CY1121350T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY1122349T1 (el) Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40
CL2008001301A1 (es) Compuestos derivados de heterociclos de nitrogeno; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una condicion inflamatoria o alergica, tal como una enfermedad inflamatoria u obstructiva de las vias respiratorias mediada por el bloqueo del canal de sodio epitelial.
CY1120342T1 (el) Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου
CY1112751T1 (el) Μεθοδος διαμορφωσης του συζευγμενου με πρωτεϊνη g υποδοχεα gpr119 και επιλεγμενες ενωσεις
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
DK1487461T3 (da) Fremgangsmåder til anvendelse af og præparater omfattende immunomodulatoriske forbindelser til behandling og håndtering af myelodysplastiske syndromer
CY1118017T1 (el) Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
DK2319517T3 (da) Anvendelse af prodrugs til okulær, intravenøs administration
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CY1105202T1 (el) Διασπειρομενες φαρμακευτικες συνθεσεις
ECSP077349A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1112499T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
ECSP088240A (es) Composición de trazodona para administración una vez por día
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
BRPI0812504B8 (pt) composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
EA200802213A1 (ru) Способы лечения заболеваний крови
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση